118 related articles for article (PubMed ID: 37269289)
1. Phosphoproteomics guides effective low-dose drug combinations against pancreatic ductal adenocarcinoma.
Vallés-Martí A; Mantini G; Manoukian P; Waasdorp C; Sarasqueta AF; de Goeij-de Haas RR; Henneman AA; Piersma SR; Pham TV; Knol JC; Giovannetti E; Bijlsma MF; Jiménez CR
Cell Rep; 2023 Jun; 42(6):112581. PubMed ID: 37269289
[TBL] [Abstract][Full Text] [Related]
2. Kinase activities in pancreatic ductal adenocarcinoma with prognostic and therapeutic avenues.
Vallés-Martí A; de Goeij-de Haas RR; Henneman AA; Piersma SR; Pham TV; Knol JC; Verheij J; Dijk F; Halfwerk H; Giovannetti E; Jiménez CR; Bijlsma MF
Mol Oncol; 2024 Apr; ():. PubMed ID: 38650175
[TBL] [Abstract][Full Text] [Related]
3. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
[TBL] [Abstract][Full Text] [Related]
4. Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma.
Le Large TYS; Bijlsma MF; El Hassouni B; Mantini G; Lagerweij T; Henneman AA; Funel N; Kok B; Pham TV; de Haas R; Morelli L; Knol JC; Piersma SR; Kazemier G; van Laarhoven HWM; Giovannetti E; Jimenez CR
J Exp Clin Cancer Res; 2021 Mar; 40(1):91. PubMed ID: 33750427
[TBL] [Abstract][Full Text] [Related]
5. The pseudokinase SgK223 promotes invasion of pancreatic ductal epithelial cells through JAK1/Stat3 signaling.
Tactacan CM; Phua YW; Liu L; Zhang L; Humphrey ES; Cowley M; Pinese M; Biankin AV; Daly RJ
Mol Cancer; 2015 Jul; 14():139. PubMed ID: 26215634
[TBL] [Abstract][Full Text] [Related]
6. Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow Tumor Growth in Mice.
Jandaghi P; Najafabadi HS; Bauer AS; Papadakis AI; Fassan M; Hall A; Monast A; von Knebel Doeberitz M; Neoptolemos JP; Costello E; Greenhalf W; Scarpa A; Sipos B; Auld D; Lathrop M; Park M; Büchler MW; Strobel O; Hackert T; Giese NA; Zogopoulos G; Sangwan V; Huang S; Riazalhosseini Y; Hoheisel JD
Gastroenterology; 2016 Dec; 151(6):1218-1231. PubMed ID: 27578530
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
8. Shared extracellular vesicle miRNA profiles of matched ductal pancreatic adenocarcinoma organoids and blood plasma samples show the power of organoid technology.
Zeöld A; Sándor GO; Kiss A; Soós AÁ; Tölgyes T; Bursics A; Szűcs Á; Harsányi L; Kittel Á; Gézsi A; Buzás EI; Wiener Z
Cell Mol Life Sci; 2021 Mar; 78(6):3005-3020. PubMed ID: 33237353
[TBL] [Abstract][Full Text] [Related]
9. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines.
Ma Y; Sender S; Sekora A; Kong W; Bauer P; Ameziane N; Krake S; Radefeldt M; Al-Ali R; Weiss FU; Lerch MM; Parveen A; Zechner D; Junghanss C; Murua Escobar H
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457227
[TBL] [Abstract][Full Text] [Related]
12. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
[TBL] [Abstract][Full Text] [Related]
13. Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma.
Hsieh YY; Liu TP; Chou CJ; Chen HY; Lee KH; Yang PM
Genes (Basel); 2019 Sep; 10(10):. PubMed ID: 31569425
[TBL] [Abstract][Full Text] [Related]
14. The ambiguous role of microRNA-205 and its clinical potential in pancreatic ductal adenocarcinoma.
Michael Traeger M; Rehkaemper J; Ullerich H; Steinestel K; Wardelmann E; Senninger N; Abdallah Dhayat S
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2419-2431. PubMed ID: 30244390
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic ductal adenocarcinoma cells employ integrin α6β4 to form hemidesmosomes and regulate cell proliferation.
Humphries JD; Zha J; Burns J; Askari JA; Below CR; Chastney MR; Jones MC; Mironov A; Knight D; O'Reilly DA; Dunne MJ; Garrod DR; Jorgensen C; Humphries MJ
Matrix Biol; 2022 Jun; 110():16-39. PubMed ID: 35405272
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
17. A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells.
Kent OA; Mullendore M; Wentzel EA; López-Romero P; Tan AC; Alvarez H; West K; Ochs MF; Hidalgo M; Arking DE; Maitra A; Mendell JT
Cancer Biol Ther; 2009 Nov; 8(21):2013-24. PubMed ID: 20037478
[TBL] [Abstract][Full Text] [Related]
18. ImmunoPET Predicts Response to Met-targeted Radioligand Therapy in Models of Pancreatic Cancer Resistant to Met Kinase Inhibitors.
Escorcia FE; Houghton JL; Abdel-Atti D; Pereira PR; Cho A; Gutsche NT; Baidoo KE; Lewis JS
Theranostics; 2020; 10(1):151-165. PubMed ID: 31903112
[No Abstract] [Full Text] [Related]
19. MiR-143-3p suppresses tumorigenesis in pancreatic ductal adenocarcinoma by targeting KRAS.
Xie F; Li C; Zhang X; Peng W; Wen T
Biomed Pharmacother; 2019 Nov; 119():109424. PubMed ID: 31521891
[TBL] [Abstract][Full Text] [Related]
20. Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma.
Tong Y; Sun M; Chen L; Wang Y; Li Y; Li L; Zhang X; Cai Y; Qie J; Pang Y; Xu Z; Zhao J; Zhang X; Liu Y; Tian S; Qin Z; Feng J; Zhang F; Zhu J; Xu Y; Lou W; Ji Y; Zhao J; He F; Hou Y; Ding C
J Hematol Oncol; 2022 Nov; 15(1):168. PubMed ID: 36434634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
